NCT02483871View on ClinicalTrials.gov

Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 10, 2017

Study Completion Date

May 10, 2017

Conditions

Breast Cancer

Interventions

DRUG

Rosuvastatin

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT02483871 - Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy | Biotech Hunter | Biotech Hunter